1-14 of 14
Jenn Lachey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Rker-050, a Modified Activin Receptor Type Iia Ligand Trap, Regulates Osteogenic Lineage, Complementing the Erythroid Response and Rebalancing the Osteo-Hematopoietic Niche

Free
Vamsee D Myneni, Mike Dills, Savanna Macaluso, Radina Todorova, Lorena Lerner, Jasbir Seehra, Jenn Lachey, Samuel Cadena
Journal: Blood
Blood (2024) 144 (Supplement 1): 5660.
https://doi.org/10.1182/blood-2024-208738
Published: 2024
Journal Articles

Activin a Inhibition Impaired Human AML Cell Engraftment and Extended Survival in Immunodeficient Mice

Free
Blake Moses, Ashlyn Wheeler, Mike Dills, Tyler Daman, Rosa Grenha, Lorena Lerner, Jasbir Seehra, Jenn Lachey, Samuel Cadena
Journal: Blood
Blood (2024) 144 (Supplement 1): 5658.
https://doi.org/10.1182/blood-2024-208031
Published: 2024
Journal Articles

Rker-216 Reversed Microcytic Anemia in a Mouse Model of Iron Refractory Iron Deficiency Anemia

Free
Chia-Yu Wang, Emiliano Melgar-Bermudez, Diana Welch, Samuel Cadena, Lorena Lerner, Jasbir Seehra, Jenn Lachey
Journal: Blood
Blood (2023) 142 (Supplement 1): 2466.
https://doi.org/10.1182/blood-2023-179253
Published: 2023
Journal Articles

Rker-050, a Modified Activin Receptor Type Iia Ligand Trap, Promoted Erythropoiesis in a Murine Model of Myelofibrosis

Free
Blake Moses, Mike Dills, Ashlyn Wheeler, Radina Todorova, Savanna Macaluso, Tyler Damen, Samuel Cadena, Lorena Lerner, Jasbir Seehra, Jenn Lachey
Journal: Blood
Blood (2023) 142 (Supplement 1): 4524.
https://doi.org/10.1182/blood-2023-178741
Published: 2023
Journal Articles

Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor Ker-047 for Treatment of Iron Refractory Iron Deficiency Anemia

Free
Vera Hoving, Albertine Donker, Enrikas Vainorius, Harveen Dhillon Natarajan, Jenn Lachey, Simon Cooper, Dorine W. Swinkels, Saskia Schols
Journal: Blood
Blood (2022) 140 (Supplement 1): 2475–2476.
https://doi.org/10.1182/blood-2022-163698
Published: 2022
Journal Articles

Rker-050, a Novel Activin Receptor Type II Ligand Trap, Rescued Anemia and Reduced Bone Loss in a Mouse Model of Myelodysplastic Syndromes

Free
Blake S Moses, Chris Materna, Remya Nathan, Tandicka Nurse, Keith Babbs, Claire Tseng, Ffolliott Fisher, Jasbir Seehra, Jenn Lachey
Journal: Blood
Blood (2022) 140 (Supplement 1): 9763–9764.
https://doi.org/10.1182/blood-2022-169360
Published: 2022
Journal Articles

ALK2 Inhibition and a Modified Activin Receptor Type Iia Ligand Trap Cotherapy Maximized Hematologic Improvements in a Mouse Model of Anemia of Inflammation

Free
Chia-Yu Wang, Emiliano Melgar-Bermudez, Diana Welch, Claire C Tseng, Ffolliott Fisher, Samuel M Cadena, Lorena Lerner, Jasbir Seehra, Jenn Lachey
Journal: Blood
Blood (2022) 140 (Supplement 1): 5337–5338.
https://doi.org/10.1182/blood-2022-166838
Published: 2022
Journal Articles

Rker-050 Rescued Ruxolitinib (Rux)-Associated Reductions in Red Blood Cell Volume

Free
Remya Nathan, Marina Feigenson, Joshua Lamora, Claire C Tseng, Ffolliott Fisher, Jasbir Seehra, Jenn Lachey
Journal: Blood
Blood (2021) 138 (Supplement 1): 934.
https://doi.org/10.1182/blood-2021-152729
Published: 2021
Journal Articles

A Monoclonal Antibody Targeting ALK2 As a Potential Therapeutic Agent for Anemia of Inflammation

Free
Natalia Medeiros, Thomas A Backus, Christopher Materna, Ffolliott Fisher, Jenn Lachey, Jasbir Seehra
Journal: Blood
Blood (2021) 138 (Supplement 1): 2007.
https://doi.org/10.1182/blood-2021-153160
Published: 2021
Journal Articles

Ker-050, an Inhibitor of TGF- β Superfamily Signaling, Promoted Thrombopoiesis and Reversed Immune Thrombocytopenia in a Mouse Model of Disease

Free
Marina Feigenson, Remya Nathan, Joshua Lamora, Ffolliott Fisher, Claire C Tseng, Jasbir Seehra, Jenn Lachey
Journal: Blood
Blood (2021) 138 (Supplement 1): 2068.
https://doi.org/10.1182/blood-2021-152814
Published: 2021
Journal Articles

A Phase 2, Open-Label, Ascending Dose Study of Ker-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Free
David M Ross, Alejandro Arbelaez, Lynette C.Y. Chee, Chun Yew Fong, Devendra Hiwase, George Kannourakis, John Kwan, James Liang, Anish Puliyayil, Hannah Rose, Shuhying Tan, Tse-Chieh Teh, David Alan Westerman, Joel Wight, Chris Rovaldi, Elissa M. Furutani, Adrienne Gaggi, Ying Jiang, Jenn Lachey, Harveen Dhillon Natarajan, Claudia Ordonez
Journal: Blood
Blood (2021) 138 (Supplement 1): 3675.
https://doi.org/10.1182/blood-2021-147335
Published: 2021
Journal Articles

Ker-050, a Modified Actriia Ligand Trap, Alleviates Cytopenia Arising from Multiple Etiologies

Free
Marina Feigenson, PhD, Remya Nathan, Keith Babbs, Christopher Materna, Claire C Tseng, PhD, Ffolliott Fisher, Jasbir Seehra, Jenn Lachey
Journal: Blood
Blood (2020) 136 (Supplement 1): 38.
https://doi.org/10.1182/blood-2020-140167
Published: 2020
Journal Articles

Ker-050, a Novel Inhibitor of Tgfβ Superfamily Signaling, Induces Red Blood Cell Production By Promoting Multiple Stages of Erythroid Differentiation

Free
Marina Feigenson, PhD, Remya Nathan, Christopher Materna, Alana Gudelsky, Evan Lema, Claire C Tseng, PhD, Ffolliott Fisher, Jasbir Seehra, Jenn Lachey
Journal: Blood
Blood (2020) 136 (Supplement 1): 34.
https://doi.org/10.1182/blood-2020-140364
Published: 2020
Journal Articles

Administration of KER-047, a Novel ALK2 Inhibitor, Elicited Robust and Sustained Increases in Serum Iron in Healthy Participants

Free
Claudia Ordonez, MD, Snyder Ben, MD, Rachel Barger, Timna Serino, Claire C Tseng, PhD, Christopher Rovaldi, M.Sc, Jenn Lachey, Jasbir Seehra
Journal: Blood
Blood (2020) 136 (Supplement 1): 13.
https://doi.org/10.1182/blood-2020-140323
Published: 2020